Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR103 HIV-1 antigen
- Development stage
- Unknown
- Lead developer
- The Immune Response
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**IR103 HIV-1 antigen** is an investigational therapeutic HIV-1 vaccine developed by The Immune Response. It combines a whole-inactivated, gp120-depleted HIV-1 immunogen containing 10 micrograms per mL p24 antigen with the CpG oligodeoxynucleotide TLR9 agonist adjuvant Amplivax, also called HYB2055, in incomplete Freund's adjuvant. Rather than directly inhibiting viral replication like antiretroviral therapy, IR103 is intended to stimulate HIV-specific cellular immune responses, including CD4-positive and CD8-positive T-cell responses, to improve immunologic control of HIV-1 infection. It was evaluated in HIV-1-infected adults, including antiretroviral-naive participants in a Phase II Italian study and later Phase III development. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/trial/2004-005050-31/IT))
- Other names
- IR103 HIV-1 antigen plus AmplivaxIR-103 HIV-1 antigen plus AmplivaxIR 103 HIV-1 antigen plus AmplivaxREMUNEX
02
Targets
Human immunodeficiency virus type 1 envelope glycoprotein (HIV-1 Env)
Beyond the preview
Go deeper on IR103 HIV-1 antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR103 HIV-1 antigen.